drugset
drugset / Trial / NCT07443202

Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE)

NCT07443202 ↗

Phase 2 Enrolling by invitation 155 enrolled Tarsus Pharmaceuticals, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate lotilaner treatment in patients with ocular rosacea.

Timeline

Start
2025-12-05
Primary completion
2026-12-31
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject lotilaner Small molecule — —

Indications

rosacea conjunctivitis